SARS-CoV-2, the causative agent for COVID-19 disease, initially reported in Wuhan, Hubei China as an outbreak of viral pneumonia. The presentation ranged from asymptomatic to a severe viral pneumonia which can be fatal in high-risk groups. Some patients also presented with gastrointestinal symptoms. Studies on its symptomatology had been widely discussed in various literatures but its effect on aminotransferases and gastrointestinal system in general were still underway. Hence, this study aimed to determine the prevalence of gastrointestinal and liver manifestations and corresponding laboratory abnormalities among COVID-19 patients admitted in a tertiary referral hospital, and to determine its associations with disease severity and clinical outcomes of COVID-19 infection. Cross-sectional study design was used. A 340-sample population was computed with a 95% confidence interval. The population consisted of randomly selected COVID-19 confirmed patients aged >19 years-old admitted at Baguio General Hospital and Medical Center from May 1, 2020 to July 31, 2021. Data were encoded in a spreadsheet; and were analyzed through frequencies, percentages, means and standard deviation. Kruskal-Wallis H Test, One-way ANOVA and Chi-square were used to test for association with <0.01 alpha level of significance. 18.23% COVID-19 patients had GI and liver manifestations. The presence of GI symptoms also showed an increased risk for developing abnormal laboratory parameters (aminotransferases, INR, inflammatory markers, and Procalcitonin). Symptoms and laboratory parameters were also associated with severe COVID-19 infection and abnormal laboratories were also associated with worse outcomes (recovery status, need for ICU admission, mortality and length of hospitalizations), except for GGT. Mild acute liver injury was common in COVID-19 patients and signified better recovery outcomes. In conclusion, these symptoms and laboratory tests provided significant associations which can be used by clinicians in tailoring specific diagnostics and therapeutics; and can simultaneously be used in prognostication of COVID-19 patients.
Published in | Biomedical Sciences (Volume 8, Issue 1) |
DOI | 10.11648/j.bs.20220801.15 |
Page(s) | 28-36 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
COVID-19, Gastrointestinal Manifestations, Liver Function Test, Severity, Outcomes
[1] | Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020; 73 (3): 566–7. |
[2] | Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–9. |
[3] | Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020; 368: m606. |
[4] | Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study: A descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020; 115 (5): 766–73. |
[5] | Ghoda A, Ghoda M. Liver injury in COVID-19 infection: A systematic review. Cureus. 2020; 12 (7): e9487. |
[6] | Mandal A, Konala VM, Adapa S, Naramala S, Gayam V. Gastrointestinal manifestations in COVID-19 infection and its practical applications. Cureus. 2020; 12 (6): e8750. |
[7] | Chau T-N, Lee K-C, Yao H, Tsang T-Y, Chow T-C, Yeung Y-C, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004; 39 (2): 302–10. |
[8] | Mao R, Qiu Y, He J-S, Tan J-Y, Li X-H, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (7): 667–78. |
[9] | Salva EP, Villarama JB, Lopez EB, Sayo AR, Villanueva AMG, Edwards T, et al. Epidemiological and clinical characteristics of patients with suspected COVID-19 admitted in Metro Manila, Philippines. Trop Med Health. 2020; 48 (1): 51. |
[10] | Haw NJL, Uy J, Sy KTL, Abrigo MRM. Epidemiological profile and transmission dynamics of COVID-19 in the Philippines. Epidemiol Infect. 2020; 148: e204. |
[11] | Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012; 487 (7408): 477–81. |
[12] | Hao S-R, Zhang S-Y, Lian J-S, Jin X, Ye C-Y, Cai H, et al. Liver enzyme elevation in Coronavirus disease 2019: A multicenter, retrospective, cross-sectional study. Am J Gastroenterol. 2020; 115 (7): 1075–83. |
[13] | Wei X-S, Wang X, Niu Y-R, Ye L-L, Peng W-B, Wang Z-H, et al. Diarrhea is associated with prolonged symptoms and viral carriage in corona virus disease 2019. Clin Gastroenterol Hepatol. 2020; 18 (8): 1753-1759. 2. |
[14] | Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020; 369 (6499): 50–4. |
[15] | Olimba LJ, MD, Tawasil A MD, Bonghanoy AA MD, Torres JJ MD, Evasan A MD, Yasay E MD, Salamat S, editors. Gastrointestinal Manifestations and Health Outcomes in patients with COVID-19 infection in a tertiary hospital. Abstract Research Presentation PDHW-JAC, PSG; 2021. |
[16] | Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: Systematic review and meta-analysis. Gastroenterology. 2020; 159 (1): 81–95. |
[17] | Cholankeril G, Podboy A, Aivaliotis VI, Tarlow B, Pham EA, Spencer SP, et al. High prevalence of concurrent gastrointestinal manifestations in patients with severe acute respiratory syndrome Coronavirus 2: Early experience from California. Gastroenterology. 2020; 159 (2): 775–7. |
[18] | Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005; 202 (3): 415–24. |
[19] | Perlman S. Another decade, another Coronavirus. N Engl J Med. 2020; 382 (8): 760–2. |
[20] | Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708–20. |
[21] | Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020; 104 (3): 246–51. |
[22] | APASL COVID-19 Task Force, Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020; 14 (4): 415–28. |
[23] | Wang Q, Zhao H, Liu L-G, Wang Y-B, Zhang T, Li M-H, et al. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil Med Res. 2020; 7 (1): 28. |
[24] | Chen LY, Chu HK, Bai T, Tu SJ, Wei Y, Li ZL, et al. Liver damage at admission is an independent prognostic factor for COVID-19. J Dig Dis. 2020; 21 (9): 512–8. |
[25] | Li HW, Ong JP, editors. Acute Liver Injury among patients with COVID-19 in a tertiary hospital. Abstract Research Presentation PDHW-JAC, PSG; 2021. |
[26] | Rodriguez BJ, Abola LE, editors. Prevalence of Elevated Transaminases Among Adult Filipino Patients with COVID-19 Infection Admitted at a Tertiary Hospital in Metro Manila from March to August 2020: A cross-sectional Analytical study. Abstract Research Presentation PDHW-JAC, PSG; 2021. |
[27] | Lei F, Liu YM, Zhou F, et al. Longitudinal association between markersof liver injury and mortality in COVID-19 in China. Hepatology. 2020; 72 (2): 389-398. |
[28] | Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020; 18 (7): 1561-1566. |
[29] | To KK-W, Tsang OT-Y, Yip CC-Y, Chan K-H, Wu T-C, Chan JM-C, et al. Consistent detection of 2019 novel Coronavirus in saliva. Clin Infect Dis. 2020; 71 (15): 841–3. |
[30] | Torres MJ, Gabriel EA, editors. Correlation between abnormal liver profile and The clinical Outcome in COVID-19 patients: A single center, Retrospective, Cohort Study. Abstract Research Presentation PDHW-JAC, PSG; 2021. |
[31] | Zeng, F., Huang, Y., Guo, Y., Yin, M., Chen, X., Xiao, L., & Deng, G. (2020). Association of inflammatory markers with the severity of COVID-19: A meta-analysis. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 96, 467–474. https://doi.org/10.1016/j.ijid.2020.05.055. |
APA Style
Charisse Begonia Ferrer, Marie Ellaine Nicer Velasquez. (2022). Association of Gastrointestinal Manifestations and Laboratory Abnormalities on Clinical Outcomes of COVID-19 Patients in a Tertiary Hospital. Biomedical Sciences, 8(1), 28-36. https://doi.org/10.11648/j.bs.20220801.15
ACS Style
Charisse Begonia Ferrer; Marie Ellaine Nicer Velasquez. Association of Gastrointestinal Manifestations and Laboratory Abnormalities on Clinical Outcomes of COVID-19 Patients in a Tertiary Hospital. Biomed. Sci. 2022, 8(1), 28-36. doi: 10.11648/j.bs.20220801.15
AMA Style
Charisse Begonia Ferrer, Marie Ellaine Nicer Velasquez. Association of Gastrointestinal Manifestations and Laboratory Abnormalities on Clinical Outcomes of COVID-19 Patients in a Tertiary Hospital. Biomed Sci. 2022;8(1):28-36. doi: 10.11648/j.bs.20220801.15
@article{10.11648/j.bs.20220801.15, author = {Charisse Begonia Ferrer and Marie Ellaine Nicer Velasquez}, title = {Association of Gastrointestinal Manifestations and Laboratory Abnormalities on Clinical Outcomes of COVID-19 Patients in a Tertiary Hospital}, journal = {Biomedical Sciences}, volume = {8}, number = {1}, pages = {28-36}, doi = {10.11648/j.bs.20220801.15}, url = {https://doi.org/10.11648/j.bs.20220801.15}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bs.20220801.15}, abstract = {SARS-CoV-2, the causative agent for COVID-19 disease, initially reported in Wuhan, Hubei China as an outbreak of viral pneumonia. The presentation ranged from asymptomatic to a severe viral pneumonia which can be fatal in high-risk groups. Some patients also presented with gastrointestinal symptoms. Studies on its symptomatology had been widely discussed in various literatures but its effect on aminotransferases and gastrointestinal system in general were still underway. Hence, this study aimed to determine the prevalence of gastrointestinal and liver manifestations and corresponding laboratory abnormalities among COVID-19 patients admitted in a tertiary referral hospital, and to determine its associations with disease severity and clinical outcomes of COVID-19 infection. Cross-sectional study design was used. A 340-sample population was computed with a 95% confidence interval. The population consisted of randomly selected COVID-19 confirmed patients aged >19 years-old admitted at Baguio General Hospital and Medical Center from May 1, 2020 to July 31, 2021. Data were encoded in a spreadsheet; and were analyzed through frequencies, percentages, means and standard deviation. Kruskal-Wallis H Test, One-way ANOVA and Chi-square were used to test for association with <0.01 alpha level of significance. 18.23% COVID-19 patients had GI and liver manifestations. The presence of GI symptoms also showed an increased risk for developing abnormal laboratory parameters (aminotransferases, INR, inflammatory markers, and Procalcitonin). Symptoms and laboratory parameters were also associated with severe COVID-19 infection and abnormal laboratories were also associated with worse outcomes (recovery status, need for ICU admission, mortality and length of hospitalizations), except for GGT. Mild acute liver injury was common in COVID-19 patients and signified better recovery outcomes. In conclusion, these symptoms and laboratory tests provided significant associations which can be used by clinicians in tailoring specific diagnostics and therapeutics; and can simultaneously be used in prognostication of COVID-19 patients.}, year = {2022} }
TY - JOUR T1 - Association of Gastrointestinal Manifestations and Laboratory Abnormalities on Clinical Outcomes of COVID-19 Patients in a Tertiary Hospital AU - Charisse Begonia Ferrer AU - Marie Ellaine Nicer Velasquez Y1 - 2022/02/25 PY - 2022 N1 - https://doi.org/10.11648/j.bs.20220801.15 DO - 10.11648/j.bs.20220801.15 T2 - Biomedical Sciences JF - Biomedical Sciences JO - Biomedical Sciences SP - 28 EP - 36 PB - Science Publishing Group SN - 2575-3932 UR - https://doi.org/10.11648/j.bs.20220801.15 AB - SARS-CoV-2, the causative agent for COVID-19 disease, initially reported in Wuhan, Hubei China as an outbreak of viral pneumonia. The presentation ranged from asymptomatic to a severe viral pneumonia which can be fatal in high-risk groups. Some patients also presented with gastrointestinal symptoms. Studies on its symptomatology had been widely discussed in various literatures but its effect on aminotransferases and gastrointestinal system in general were still underway. Hence, this study aimed to determine the prevalence of gastrointestinal and liver manifestations and corresponding laboratory abnormalities among COVID-19 patients admitted in a tertiary referral hospital, and to determine its associations with disease severity and clinical outcomes of COVID-19 infection. Cross-sectional study design was used. A 340-sample population was computed with a 95% confidence interval. The population consisted of randomly selected COVID-19 confirmed patients aged >19 years-old admitted at Baguio General Hospital and Medical Center from May 1, 2020 to July 31, 2021. Data were encoded in a spreadsheet; and were analyzed through frequencies, percentages, means and standard deviation. Kruskal-Wallis H Test, One-way ANOVA and Chi-square were used to test for association with <0.01 alpha level of significance. 18.23% COVID-19 patients had GI and liver manifestations. The presence of GI symptoms also showed an increased risk for developing abnormal laboratory parameters (aminotransferases, INR, inflammatory markers, and Procalcitonin). Symptoms and laboratory parameters were also associated with severe COVID-19 infection and abnormal laboratories were also associated with worse outcomes (recovery status, need for ICU admission, mortality and length of hospitalizations), except for GGT. Mild acute liver injury was common in COVID-19 patients and signified better recovery outcomes. In conclusion, these symptoms and laboratory tests provided significant associations which can be used by clinicians in tailoring specific diagnostics and therapeutics; and can simultaneously be used in prognostication of COVID-19 patients. VL - 8 IS - 1 ER -